- Home
- GTBP vs ADTX Comparison
GTBP vs ADTX Comparison
Compare GTBP & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- ADTX
- Stock Information
- Founded
- GTBP 1965
- ADTX 2017
- Country
- GTBP United States
- ADTX United States
- Employees
- GTBP N/A
- ADTX N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- ADTX Health Care
- Exchange
- GTBP Nasdaq
- ADTX Nasdaq
- Market Cap
- GTBP 5.6M
- ADTX 5.3M
- IPO Year
- GTBP N/A
- ADTX 2020
- Fundamental
- Price
- GTBP $2.36
- ADTX $5.00
- Analyst Decision
- GTBP Strong Buy
- ADTX
- Analyst Count
- GTBP 1
- ADTX 0
- Target Price
- GTBP $11.00
- ADTX N/A
- AVG Volume (30 Days)
- GTBP 33.2K
- ADTX 8.1M
- Earning Date
- GTBP 05-14-2025
- ADTX 05-19-2025
- Dividend Yield
- GTBP N/A
- ADTX N/A
- EPS Growth
- GTBP N/A
- ADTX N/A
- EPS
- GTBP N/A
- ADTX N/A
- Revenue
- GTBP N/A
- ADTX $133,985.00
- Revenue This Year
- GTBP N/A
- ADTX $95.61
- Revenue Next Year
- GTBP N/A
- ADTX $1,584.79
- P/E Ratio
- GTBP N/A
- ADTX N/A
- Revenue Growth
- GTBP N/A
- ADTX N/A
- 52 Week Low
- GTBP $1.72
- ADTX $4.11
- 52 Week High
- GTBP $10.66
- ADTX $35,000.00
- Technical
- Relative Strength Index (RSI)
- GTBP 50.10
- ADTX 33.28
- Support Level
- GTBP $2.10
- ADTX $4.17
- Resistance Level
- GTBP $2.45
- ADTX $7.69
- Average True Range (ATR)
- GTBP 0.18
- ADTX 1.92
- MACD
- GTBP -0.01
- ADTX 0.36
- Stochastic Oscillator
- GTBP 56.43
- ADTX 10.10
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.